109 related articles for article (PubMed ID: 31331295)
1. Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts.
Cornillie J; Wozniak A; Van Renterghem B; Van Winkel N; Wellens J; Gebreyohannes YK; Debiec-Rychter M; Sciot R; Hompes D; Schöffski P
BMC Cancer; 2019 Jul; 19(1):724. PubMed ID: 31331295
[TBL] [Abstract][Full Text] [Related]
2. Developments in the management of advanced soft-tissue sarcoma - olaratumab in context.
Moroncini G; Maccaroni E; Fiordoliva I; Pellei C; Gabrielli A; Berardi R
Onco Targets Ther; 2018; 11():833-842. PubMed ID: 29497315
[TBL] [Abstract][Full Text] [Related]
3. The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy.
Sampson ER; Amin V; Schwarz EM; O'Keefe RJ; Rosier RN
J Orthop Res; 2011 Apr; 29(4):623-32. PubMed ID: 20957741
[TBL] [Abstract][Full Text] [Related]
4. Olaratumab: A New Strategy in the Treatment of Advanced Soft-Tissue Sarcoma.
Moore DC; Lavery LA
J Adv Pract Oncol; 2018 Mar; 9(2):235-240. PubMed ID: 30588358
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice.
Gupta B; Torchilin VP
Cancer Immunol Immunother; 2007 Aug; 56(8):1215-23. PubMed ID: 17219149
[TBL] [Abstract][Full Text] [Related]
6. Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas.
Nakano K; Takahashi S
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29510588
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the treatment strategies on patient-derived xenograft mice of human breast tumor.
Khalighfard S; Alizadeh AM; Poorkhani A; Motahari M; Tahmasebifar A; Omranipour R; Keshavarz P; Haddad P
Eur J Pharmacol; 2020 Dec; 889():173605. PubMed ID: 32980347
[TBL] [Abstract][Full Text] [Related]
8. Generation of post-surgical minimal residual disease models to investigate metastasis in soft tissue sarcoma patient-derived orthotopic xenografts.
Fischer S; Creytens D; Gijsels S; Descamps B; Lapeire L; Hendrix A; Sys G; De Wever O
STAR Protoc; 2024 Mar; 5(1):102863. PubMed ID: 38421864
[TBL] [Abstract][Full Text] [Related]
9. Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies.
Lahat G; Zhu QS; Huang KL; Wang S; Bolshakov S; Liu J; Torres K; Langley RR; Lazar AJ; Hung MC; Lev D
PLoS One; 2010 Apr; 5(4):e10105. PubMed ID: 20419128
[TBL] [Abstract][Full Text] [Related]
10. Enhanced Antipediatric Sarcoma Effect of Everolimus with Secukinumab by Targeting IL17A.
Huang D; Wu Z; Wu Z; Li N; Hao L; Li K; Zeng J; Qiu B; Zhang S; Yan J
Mol Cancer Ther; 2024 May; 23(5):721-732. PubMed ID: 38295302
[TBL] [Abstract][Full Text] [Related]
11. Best Overall Response-associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE.
Liu J; Moura DS; Jones RL; Aggarwal A; Philip EJ; Wagner AJ; Wright J; Martín-Broto J; Tap WD
Clin Cancer Res; 2024 Mar; ():. PubMed ID: 38536068
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States.
Zuluaga-Sanchez S; Hess LM; Wolowacz SE; D'yachkova Y; Hawe E; Vickers AD; Kaye JA; Bertwistle D
Sarcoma; 2018; 2018():6703963. PubMed ID: 29785170
[TBL] [Abstract][Full Text] [Related]
13. Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations.
In GK; Hu JS; Tseng WW
Ther Adv Med Oncol; 2017 Aug; 9(8):533-550. PubMed ID: 28794805
[TBL] [Abstract][Full Text] [Related]
14. Establishment of a novel canine soft tissue sarcoma cell line and comparison of its characteristics with other soft tissue sarcoma cell lines.
Miyanishi K; Igase M; Murakami M; Sakai Y; Sakurai M; Tani K; Motegi T; Mizuno T
Res Vet Sci; 2024 May; 171():105245. PubMed ID: 38554610
[TBL] [Abstract][Full Text] [Related]
15. Characterisation of new in vitro models and identification of potentially active drugs in angiosarcoma.
Mendiola M; Saarela J; Escudero FJ; Heredia-Soto V; Potdar S; Rodriguez-Marrero S; Miguel M; Pozo-Kreilinger JJ; Berjon A; Ortiz-Cruz E; Feliu J; Redondo A
Biomed Pharmacother; 2024 Apr; 173():116397. PubMed ID: 38479181
[TBL] [Abstract][Full Text] [Related]
16. LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications.
Ben-Ami E; Perret R; Huang Y; Courgeon F; Gokhale PC; Laroche-Clary A; Eschle BK; Velasco V; Le Loarer F; Algeo MP; Purcell J; Demetri GD; Italiano A
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32210091
[TBL] [Abstract][Full Text] [Related]
17. The Synergy of
Tseng JR; Hsu CL; Hsieh HH; Ho KC; Chung YH; Wu CY
Biomed J; 2024 May; ():100744. PubMed ID: 38729609
[TBL] [Abstract][Full Text] [Related]
18. Assessing Protein Expression in Patient-Derived Xenografts Using Western Blotting.
Rossi Herling B; Chen MZ; McLeod VM
Methods Mol Biol; 2024; 2806():209-218. PubMed ID: 38676805
[TBL] [Abstract][Full Text] [Related]
19. Depletion of Mouse Cells from Human Tumor Xenografts Significantly Improves Downstream Analysis of Target Cells.
Agorku DJ; Tomiuk S; Klingner K; Wild S; Rüberg S; Zatrieb L; Bosio A; Schueler J; Hardt O
J Vis Exp; 2016 Jul; (113):. PubMed ID: 27501218
[TBL] [Abstract][Full Text] [Related]
20. A Case Study of a Rare Undifferentiated Spindle Cell Sarcoma of the Penis: Establishment and Characterization of Patient-Derived Models.
Sousa ACDS; Fernandes BLNC; da Silva JPA; Stevanato Filho PR; Coimbra LBCT; de Oliveira Beserra A; Alvarenga AL; Maida G; Guimaraes CT; Nakamuta IM; Marchi FA; Alves C; Lichtenfels M; de Farias CB; Kupper BEC; Costa FD; de Mello CAL; Carraro DM; Torrezan GT; Lopes A; Dos Santos TG
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
